Edward S. Kim named physician-in-chief of City of Hope Orange County

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Edward S. Kim was named senior vice president and vice physician-in-chief at City of Hope, and physician-in-chief at City of Hope Orange County.

As City of Hope Orange County’s chief physician, he will be responsible for driving innovation in cancer care and delivery for the Orange County network of care and the planned Irvine campus.

He is an expert in molecular prognostication for lung, head and neck cancers.

Kim is a former chair of Solid Tumor Oncology and Investigational Therapeutics, the Donald S. Kim Distinguished Chair for Cancer Research, and medical director of the Clinical Trials Office at the Levine Cancer Institute, Atrium Health. Kim was also a professor of medicine at the University of North Carolina, Chapel Hill.

Prior to the Levine Cancer Institute, he held many leadership positions including associate tenured professor in the Department of Thoracic/Head and Neck Medical Oncology at Texas MD Anderson Cancer Center. Kim has recently completed his Masters in Business Administration at the University of North Carolina Kenan-Flagler School of Business.

Table of Contents

YOU MAY BE INTERESTED IN

For nearly 25 years, business executive Lou Weisbach and urologist Richard J. Boxer have argued that finding the money to finance the cures for devastating diseases is not as difficult as it appears. To start finding the cures, the U.S. Department of the Treasury needs to issue some bonds—$750 billion worth. Next, you hire CEOs—one...

There is general agreement that the United States spends too much on health care, especially on pharmaceuticals.  But what we spend on drugs is not simply a function of price. If eggs double in price, people can simply cut the number of eggs they eat in half.  Simply stated, cost is the product of (price per unit times the number of units purchased). 
What did President Richard M. Nixon and Senator Edward M. Kennedy have in common? They each played a pivotal role in the passage of the National Cancer Act signed by Nixon on Dec. 23, 1971. The NCA established the National Cancer Program authorizing the initial investment in the NCI-designated Cancer Centers Program. 
When I first proposed targeting PCNA (proliferating cell nuclear antigen) as a therapeutic approach, the response I got was: “No one will ever make a drug against PCNA. It’s undruggable.” The protein lacks enzymatic activity, has a disordered region, and binds to over 200 other proteins within the cell. From a traditional drug development perspective, these characteristics made PCNA an impossible target.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login